Fenwick Represents Paragraf in Acquisition of Cardea Bio

Fenwick is representing Paragraf, a producer graphene electronics using transfer-free graphene and standard semiconductor processes, in its acquisition of Cardea Bio, a producer of graphene-based biocompatible chips. Cardea Bio will be renamed Paragraf USA.

The acquisition of Cardea Bio enables Paragraf to offer a new generation of biosensing devices that will deliver the features and result sensitivity of existing lab-based instruments, with the rapid response and simple ease of use required to enable handheld, real-time, in the field use. More information can be obtained from Paragraf’s announcement.

The Fenwick transaction team included corporate partner Steve Fisher and associates Christina Kwak, Zoe Zhang and Brandon Ho; technology transactions partners Jonathan Millard and Rufus Pichler and associate Kehl Sink; executive compensation and employee benefits partner Marshall Mort and associates Jonathan Stephenson and Jennifer Lin; privacy and cybersecurity counsel Ana Razmazma and associate Alyona Eidinger; patent partner Antonia Sequeira and associate Fredrick Tsang; and tax partner Mike Knobler and associate Jenna Grove.